Legend Biotech Presents Positive Long-Term cilta-cel Data, Highlighting Advancements in Solid Tumor Pipeline

SOMERSET, N.J. – Legend Biotech Corporation (NASDAQ: LEGN) announced new long-term results from the CARTITUDE-1 study, showing CARVYKTI® (cilta-cel) achieved an unprecedented 33% progression-free rate for five years or more in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients after a single infusion. These significant data were presented at the 2025 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

The median overall survival was 60.7 months. Dr. Sundar Jagannath of Mount Sinai highlighted the “remarkable durability and consistency,” while Dr. Mythili Koneru of Legend Biotech called it a “potential paradigm shift” for RRMM treatment.

Additional ASCO presentations included positive data from the CARTITUDE-4 study, demonstrating CARVYKTI®’s consistent and durable benefit in progression-free survival (PFS) and overall survival (OS) across high-risk subgroups of relapsed, lenalidomide-refractory multiple myeloma patients compared to standard of care.

Legend Biotech also presented preliminary Phase 1 results for its solid tumor pipeline: LB1908 (CLDN18.2-targeted CAR T-cell therapy for gastroesophageal cancers) showed manageable safety and antitumor activity, and LB2102 (DLL3-targeted CAR-T cell therapy for lung cancers, licensed to Novartis) demonstrated promising safety and tolerability with signs of efficacy.

CEO Ying Huang emphasized Legend Biotech’s dedication to leveraging cell therapy to create “paradigm-shifting treatments and potential cures for cancer patients.”